Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of “Moderate Buy” by Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $16.75.

Separately, William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday.

Alto Neuroscience Price Performance

Alto Neuroscience stock traded down $0.03 during trading hours on Friday, hitting $2.66. The stock had a trading volume of 123,155 shares, compared to its average volume of 358,157. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 1-year low of $2.60 and a 1-year high of $18.35. The stock’s fifty day moving average is $3.67 and its two-hundred day moving average is $6.22.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09. As a group, analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

Several hedge funds have recently made changes to their positions in ANRO. Jennison Associates LLC lifted its holdings in shares of Alto Neuroscience by 80.3% in the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after purchasing an additional 370,612 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Alto Neuroscience by 182.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after acquiring an additional 120,779 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Alto Neuroscience by 84.5% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock valued at $753,000 after acquiring an additional 30,135 shares in the last quarter. FMR LLC raised its stake in Alto Neuroscience by 1.4% during the 3rd quarter. FMR LLC now owns 2,363,056 shares of the company’s stock valued at $27,033,000 after acquiring an additional 32,040 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after acquiring an additional 3,715 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.